MedTrace Logo

Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients

NCT00220493 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2007-01-05

No results posted yet for this study

Summary

Scientific background:

Growing awareness and accumulating data regarding the cognitive impairment and its progression in multiple sclerosis (MS) patients has received an important place in neurological research in the last decade.

Conditions

  • Relapsing Remitting Multiple Sclerosis
  • Multiple Sclerosis, Chronic Progressive

Interventions

DRUG

Ritalin

Sponsors & Collaborators

  • Sheba Medical Center

    lead OTHER_GOV

Principal Investigators

  • Anat Achiron, MD PhD · Sackler School of Medicine

  • Yirmiyahu Harel, MD · Sachler School of Medicine

  • Nava Appleboim-Gavish, MA · Sheba Medical Center at Tel Hashomer Israel

Study Design

Allocation
RANDOMIZED
Purpose
ECT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Completion
2005-06-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00220493 on ClinicalTrials.gov